National Pharmacare, Reference-Based Pricing, and Drug R&D: A Critique of the National Forum on Health's Recommendations for Pharmaceutical Policy

Charles Lindsey () and Douglas West

Canadian Public Policy, 1999, vol. 25, issue 1, 1-27

Abstract: In February 1997, the Canadian National Forum on Health presented its recommendations for a pharmaceutical policy for Canada. These recommendations include moving towards a universal coverage, publicly funded drug plan; support for reference-based pricing as a method of containing drug plan costs; and requiring that pharmaceutical companies turn over a portion of their research funds to the national research granting agencies. This paper provides a critical assessment of these policy recommendations, with a focus on whether they are likely to achieve long-term reductions in pharmaceutical and health care expenditures in Canada.

Date: 1999
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://links.jstor.org/sici?sici=0317-0861%2819990 ... PRPAD%3E2.0.CO%3B2-6 (text/html)
only available to JSTOR subscribers

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cpp:issued:v:25:y:1999:i:1:p:1-27

Ordering information: This journal article can be ordered from
https://www.utpjournals.com/loi/cpp/

Access Statistics for this article

Canadian Public Policy is currently edited by Prof. Mike Veall

More articles in Canadian Public Policy from University of Toronto Press University of Toronto Press Journals Division 5201 Dufferin Street Toronto, Ontario, Canada M3H 5T8.
Bibliographic data for series maintained by Iver Chong ( this e-mail address is bad, please contact ).